We build biotech
for the future.
AI-accelerated. Platform-driven. Venture-minded.
QADR Biotechnology is a next-generation holding company developing science-led ventures, therapeutic concepts, and health brands through an AI-accelerated model of discovery, validation, and value creation.
We don't inherit a legacy.
We construct a method.
Biotechnology is entering a programmable era. The old model — fragmented, slow, artisanal — is being replaced by something faster, more precise, and more intelligent. QADR was designed for that transition.
From signal to scale.
We identify emerging scientific opportunities before they become obvious.
We frame IP, scientific narrative, and strategic positioning.
AI compresses timelines across discovery, validation, and formulation.
We create ventures, platforms, and health brands with market logic.
We design assets for reproducibility and long-term value creation.
We identify emerging scientific opportunities before they become obvious.
We frame IP, scientific narrative, and strategic positioning.
AI compresses timelines across discovery, validation, and formulation.
We create ventures, platforms, and health brands with market logic.
We design assets for reproducibility and long-term value creation.
Built differently, by design.
We think from the next decade backward, not from yesterday forward.
AI is embedded in the engine: exploration, prioritization, formulation, execution.
We build reproducible systems, not isolated projects.
Building for the long horizon.
QADR is early-stage by timeline, future-stage by design.
GutRecover Therapeutics
Science-led gut health therapeutics — the primary operating entity of the QADR group.
Stryō
Performance and recovery, built with science-grounded discipline.
Muihā
Precision health replenishment at the intersection of science and daily ritual.
Biomaē
Microbiome-informed wellness grounded in the gut-body axis.
Biotech is entering a programmable era.
QADR is built for the transition.
Where science, AI, and venture creation converge.
Work with us.
We engage with scientists, investors, and partners building in the same direction.
The infrastructure we've built.
QADR is not defined by a single product or a single pipeline. It is defined by its system — a repeatable model for identifying, structuring, accelerating, and building high-impact biotech assets.
A system for building biotech, faster.
QADR operates as an AI-native holding structure. At the holding level, we identify scientific opportunities, frame IP strategy, and define venture architectures. At the venture level, we execute: scientific validation, product development, brand positioning, and market entry. AI is present at every layer — not as a marketing claim, but as a functional accelerant in research, formulation, prioritization, and execution.
Signal to scale, in detail.
We identify emerging scientific opportunities before they become obvious.
We scan adjacent spaces where emerging science, unmet need, and commercial opportunity intersect. We prioritize areas where AI can compress the distance between insight and asset.
We frame IP, narrative, and strategic positioning.
We architect the venture before we build it. IP positioning, scientific narrative, regulatory pathway, and market framing defined before significant capital deployment.
AI compresses timelines across discovery and formulation.
We use AI across discovery (literature synthesis, target identification), formulation (prediction and optimization), and execution (operational compression of timelines).
We create ventures with internal discipline and commercial logic.
We create ventures with defined milestones, brand architecture, commercial logic, and platform scalability from day one.
We design assets for reproducibility and long-term value.
Every asset we build is designed to compound — in evidence, in brand equity, in market position.
We scan adjacent spaces where emerging science, unmet need, and commercial opportunity intersect.
IP positioning, scientific narrative, regulatory pathway, and market framing defined before capital deployment.
AI across discovery, formulation prediction, and operational compression of timelines.
Defined milestones, brand architecture, commercial logic, and platform scalability from day one.
Every asset designed to compound — in evidence, brand equity, and market position.
What we bring to every venture.
Scientific Opportunity Identification
Systematic scanning of adjacent spaces where science, unmet need, and commercial timing align.
IP Architecture & Strategy
Positioning intellectual property before capital deployment — framing the asset before building it.
AI-Accelerated Discovery
Literature synthesis, target identification, and opportunity prioritization through applied AI.
Venture Architecture & Structuring
Legal, scientific, and operational scaffolding designed for reproducibility and scale.
Brand & Product Development
From scientific narrative to market-ready brand — built with precision, not convention.
Strategic Capital & Partnership Design
Structuring capital and partnership arrangements that match the asset's stage and trajectory.
We partner with scientific founders, IP holders, and institutional partners.
Explore partnership opportunities →The portfolio in motion.
Four ventures. One holding model. Built to compound.
QADR currently operates four active ventures across therapeutic development, consumer health, and microbiome-informed wellness. Each was architected within the QADR holding model — structured IP, defined market positioning, and AI-accelerated execution from day one.
Therapeutic · Gut Health
GutRecover Therapeutics
Science-led therapeutics for gut health and recovery.
GutRecover Therapeutics is the primary operating entity of the QADR group. It develops science-grounded formulations and therapeutic concepts addressing the gut health market — combining validated science, AI-accelerated formulation, and brand discipline.
GutRecover Therapeutics LLC · Delaware, USA
Learn more →Consumer Health · Performance & Recovery
Stryō
Performance and recovery, built with discipline.
Stryō is a direct-to-consumer health brand designed around performance support and recovery science. Built within the QADR model: science-grounded formulas, precision brand positioning, and AI-accelerated content and operations.
stryo.store →Consumer Health · Precision Replenishment
Muihā
Precision health replenishment.
Muihā is a health replenishment brand positioned at the intersection of science and daily ritual. It delivers targeted nutritional support grounded in microbiome and metabolic health science.
muiha-replenisher.com →Microbiome · Wellness
Biomaē
Microbiome-informed wellness.
Biomaē is QADR's microbiome-focused consumer brand, delivering wellness products grounded in the science of the gut-body axis. Formerly Microbiomae — repositioned and sharpened under the QADR platform model.
microbiomae.shop →Building in the same space? We partner with scientific founders and IP-driven teams.
Explore partnerships →A new operating model for biotech.
We built QADR around a thesis: the traditional biotech model is too slow, too fragmented, and too dependent on legacy infrastructure. We designed something faster.
Biotech is entering a programmable era.
Traditional biotechnology operates in decades. Discovery to patient takes 10–15 years on average. The system is expensive, artisanal, and fragmented — each step performed by different actors with different incentives and no unified view of the whole.
AI changes this. Not by removing science — but by compressing the distance between scientific insight and structured asset. Faster literature synthesis. Better target identification. AI-assisted formulation and optimization. Smarter prioritization at every stage.
QADR was built for this transition. We don't wait for the industry to catch up. We operate with the tools and methods of the next era, applied today.
From signal to scale.
Identifying opportunity before it becomes obvious.
We scan adjacent spaces where emerging science, unmet need, and commercial opportunity intersect. We prioritize areas where AI can compress the distance between insight and asset.
Architecting the venture before building it.
IP positioning, scientific narrative, regulatory pathway, and market framing defined before significant capital deployment. We design the asset before we fund it.
AI as a functional accelerant at every layer.
We use AI across discovery (literature synthesis, target identification), formulation (prediction and optimization), and execution (operational compression of timelines).
Ventures with defined milestones and commercial logic.
Internal discipline at every stage: defined milestones, brand architecture, commercial logic, and platform scalability designed into the venture from day one.
Assets designed to compound over time.
Every asset we build is designed to compound — in evidence, in brand equity, in market position. Reproducibility is a design constraint, not an afterthought.
We scan adjacent spaces where emerging science, unmet need, and commercial opportunity intersect.
IP positioning, scientific narrative, regulatory pathway, and market framing defined before capital deployment.
AI across discovery, formulation prediction, and operational compression of timelines.
Defined milestones, brand architecture, commercial logic, and platform scalability from day one.
Every asset designed to compound — in evidence, brand equity, and market position.
Not a marketing claim.
An operating reality.
Literature synthesis, opportunity mapping, target identification — applied systematically across the portfolio.
AI-assisted ingredient optimization, efficacy prediction, and safety screening across therapeutic and consumer health products.
Content generation, brand execution, and workflow automation across all ventures — reducing time from insight to market.
One platform. Four ventures.
One method.
QADR Biotechnology Holding SARLAU is the parent structure. It owns the IP, the brand architectures, and the operating methodology. Each venture operates with defined autonomy under the holding umbrella — sharing infrastructure, scientific resources, and AI tooling.
Interested in applying this model to your own scientific opportunity?
Contact us →Designed from day one for
the next era of biotech.
We started with the question,
not the answer.
QADR Biotechnology was founded on a simple but demanding thesis: that the next generation of valuable biotech assets will be built by teams who combine scientific rigor with AI-native execution and strategic discipline — not teams who inherit large infrastructure and move slowly inside it.
We are deliberately early-stage. We have chosen to build the method before scaling the portfolio, to design the holding structure before filling it with assets, and to establish the brand architecture before generating the revenue. We believe that the quality of how we build is what determines the quality of what we build.
QADR is a holding company, not a product company. It is an operating model, not a pipeline. It is a system designed to produce high-impact health ventures — and to do so faster, smarter, and with greater execution discipline than the traditional model allows.
A holding model built for international execution.
QADR Biotechnology Holding SARLAU
Casablanca, Morocco
Holding entity. Owns the IP, brand architectures, and operating methodology. Defines the venture model and manages portfolio-level strategy and AI infrastructure.
GutRecover Therapeutics LLC
Delaware, USA
Primary operating entity. Therapeutic development, DTC brands, and venture execution. The operational arm of the QADR portfolio.
Early by timeline.
Future by design.
We are a young company. We say this not defensively but precisely: we have been building the infrastructure — legal, scientific, operational, and AI — before building the revenue. We believe this is the right sequence. The ventures we launch from this foundation will carry its discipline.
"We don't inherit a legacy. We construct a method."
Built by people who think in systems.
QADR is currently in a lean founding phase. Team information will be published as the company moves into its next stage of development.
If you're building in the same direction, we want to hear from you.
Contact us →Work with us.
We engage with scientists, investors, and strategic partners who are building in the same direction.
We partner with scientific founders, IP holders, and research teams with relevant assets in microbiome, gut health, and adjacent therapeutic areas.
Subject: Partnership
We engage with investors, family offices, and funds interested in early-stage AI-native biotech holdings with a portfolio approach.
Subject: Investor Relations
QADR Biotechnology Holding SARLAU
Casablanca, Morocco
Holding entity
GutRecover Therapeutics LLC
Delaware, USA
Primary operating entity
We respond to all relevant inquiries within 3 business days.
LinkedIn →